It was a busy week for the biotech sector, with lots of regulatory and pipeline updates amid fears of a global recession ...

Merck & Co/MSD has agreed to buy Pandion for $1.85 billion, bolting on a pipeline of drugs for autoimmune and other immunological disorders headed by interleukin-2 (IL-2) based therapy PT-101 ...